Effect of gluten and wheat on symptoms and behaviours in adults with irritable bowel syndrome: a single-centre, randomised, double-blind, sham-controlled crossover trial

Irritable Bowel Syndrome (IBS) and Chronic Constipation

A novel, IBS-specific IgG ELISA-based elimination diet in irritable bowel syndrome: A randomized, sham-controlled trial

Gastroenterology

Singh P, Chey WD, Takakura W, Cash BD, Lacy BE, Quigley EMM, Randall CW, Lembo A

doi: 10.1053/j.gastro.2025.01.223

RECOMMENDED

Inflammatory Bowel Disease

Yoga for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

★ 1 Recommended by Prof. Dr Stephan Vavricka, Faculty Member

Am J Gastroenterol

Saab O, Al-Obaidi H, Algodi M, Algodi A, Rashid Y, Al-Sagban A, Albayyaa M, Merza N, Alzubaidy L, Cash B

doi: 10.14309/ajg.0000000000003524

Gastrointestinal Cancer

Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial

Lancet Gastroenterol Hepatol

Chia JWK, Segelov E, Deng Y, Ho GF, Wang W, Han S, Sharma A, Ding K, Chen G, Jeffery MG, Tham CK, Ahn JB, Nott L, Zielinski R, Chao TY, van Hagen T, Wei PL, Day F, Mehta S, Yau T, Peng J, Hayes TM, Li Y, Gandhi M, Foo EMJ, Rahman N, Rothwell P, Ali R, Simes J, Toh HC

doi: 10.1016/S2468-1253(24)00387-X

Inflammatory Bowel Disease

Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial

Lancet Gastroenterol Hepatol

D'Haens G, Taxonera C, Lopez-Sanroman A, Nos P, Danese S, Armuzzi A, Roblin X, Peyrin-Biroulet L, West R, Mares WGN, Duijvestein M, Gecse KB, Feagan BG, Zou G, Hulshoff MS, Mookhoek A, Oldenburg L, Clasquin E, Bouhnik Y, Laharie D

doi: 10.1016/S2468-1253(24)00317-0

RECOMMENDED

Inflammatory Bowel Disease

Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial

★ 3 Recommended by Prof. Dr Stephan Vavricka, Faculty Member

Lancet Gastroenterol Hepatol

Danese S, Allegretti JR, Schreiber S, Peyrin-Biroulet L, Jairath V, D'Haens G, Kierkuś J, Leong RW, Yarur AJ, Vincent MS, Banerjee A, Chandra DE, Peeva E, Neelakantan S, Hung KE, McBride JM, Bojic D, Lasch K, Schiffman C, Feagan BG

doi: 10.1016/S2468-1253(25)00129-3

Inflammatory Bowel Disease

Surveillance in inflammatory bowel disease: white light endoscopy with segmental re-inspection versus dye-based chromoendoscopy - a multi-arm randomised controlled trial (HELIOS)

Gut

Te Groen M, Wijnands AM, den Broeder N, de Jong DJ, van Dop WA, Duijvestein M, Fidder HH, van Schaik F, Hirdes MMC, van der Meulen-de Jong AE, Maljaars PWJ, Voorneveld PW, de Boer KHN, Peters CP, Oldenburg B, Hoentjen F, Dutch Initiative on Crohn and Colitis

doi: 10.1136/gutjnl-2024-333446

Inflammatory Bowel Disease

Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU

Gut

Gisbert JP, Donday MG, Riestra S, Lucendo AJ, Benítez JM, Navarro-Llavat M, Barrio J, Morales-Alvarado VJ, Rivero M, Busquets D, Leo Carnerero E, Merino O, Nantes Castillejo Ó, Navarro P, Van Domselaar M, Gutiérrez A, Alonso-Abreu I, Mejuto R, Fernández-Salazar L, Iborra M, Martín-Arranz MD, Pineda JR, Sampedro MJ, Serra Nilsson K, Bouhmidi A, Batista L, Muñoz Villafranca C, Rodríguez-Lago I, Ceballos D, Guerra I, Mañosa M, Marín Jiménez I, Torrella E, Vera Mendoza M, Casanova MJ, de Francisco R, Arias-González L, Marín Pedrosa S, García-Bosch O, García-Alonso FJ, Delgado-Guillena P, García MJ, Torrealba L, Núñez-Ortiz A, Vicuña Arregui M, Bosca-Watts MM, Blázquez I, Acosta D, Garre A, Baldán M, Martínez C, Barreiro-de Acosta M, Domènech E, Esteve M, García-Sánchez V, Nos P, Panés J, Chaparro M, EXIT Study group of GETECCU

doi: 10.1136/gutjnl-2024-333385

Gastrointestinal Cancer

Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients: The SAKK 41/13 - Prospective Randomized Placebo-Controlled Double-Blind Trial

Clin Cancer Res

Güller U, Hayoz S, Horber D, Jochum W, De Dosso S, Koeberle D, Schacher S, Inauen R, Stahl M, Delaunoit T, Ettrich T, Bodoky G, Michel P, Koessler T, Rothgiesser K, Calmonte S, Joerger M

doi: 10.1158/1078-0432.CCR-24-4048

Inflammatory Bowel Disease

Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Trial

Clin Gastroenterol Hepatol

Jairath V, D'Haens G, Sands BE, Travis S, Chaparro M, Peyrin-Biroulet L, Chen MH, Dubinsky M, Ferrante M, Schreiber S, McGinnis K, Vadhariya A, Appelmans S, Lin Z, Yu G, Protic M, Moses R, Ghosh S

doi: 10.1016/j.cgh.2025.07.003

Related content

A novel, IBS-specific IgG ELISA-based elimination diet in irritable bowel syndrome: A randomized, sham-controlled trial

Yoga for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial

Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial

Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial

Surveillance in inflammatory bowel disease: white light endoscopy with segmental re-inspection versus dye-based chromoendoscopy - a multi-arm randomised controlled trial (HELIOS)

Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU

Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients: The SAKK 41/13 - Prospective Randomized Placebo-Controlled Double-Blind Trial

Bowel Urgency in Crohn's Disease: Effects of Mirikizumab in a Randomized Controlled Phase 3 Trial